Put companies on watchlist
Alzchem Group AG
ISIN: DE000A2YNT30
WKN: A2YNT3
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Alzchem Group AG · ISIN: DE000A2YNT30 · EQS - Company News (77 News)
Country: Germany · Primary market: Germany · EQS NID: 1432203
31 August 2022 02:23PM

Alzchem and Crearene Develop Treatments for the Dialysis Market



DGAP-Media / 31.08.2022 / 14:23 CET/CEST

Joint Press Release Alzchem and Crearene

Alzchem Group AG and Crearene AG, based in Frauenfeld in Switzerland, have agreed on an exclusive memo of understanding (MOU) for the development and commercialization of Creapure®/creatine-based treatment solutions in dialysis.

Dialysis is a treatment method which is applied for patients with a compromised kidney function, and which removes toxins, waste substances and salts from the blood.

Dr. Jürgen Bezler (Vice President, Human Nutrition, Alzchem): “The improvement of the quality of life for dialysis patients is the target of this very promising cooperation with Crearene AG. Scientific research and numerous studies demonstrate that dialysis patients structurally suffer from low concentrations of creatine. Furthermore, they lose additional significant amounts of the body-own substance creatine during dialysis treatments and hence cope with drastic health impediments, such as increased muscle loss, extreme fatigue, weakening of the immune system and stressful psychological conditions, e. g. depressions. This is where the new treatment solution with Creapure®/creatine can add value. This therapeutic area will provide another attractive market opportunity for Alzchem in the health care industry.”

Dr. Frank Heideloff (CEO, Crearene AG) explains: “Today, there are more than 3 million dialysis patients in the world who rely on regular treatment. In some established healthcare markets, governments have highlighted a need for increased efforts in research to bring to market innovations for a better life for dialysis patients. Together with Alzchem we are working on enabling new treatment solutions to improve the overall quality of life, the general physical conditions and wellbeing of the increasing number of global dialysis patients. The patented know-how of Crearene, result of many years of research on the use of creatine, in combination with the manufacturing excellence of Alzchem are an excellent base for this undertaking.”

About Alzchem

Alzchem is a globally active specialty chemicals company that is one of the market leaders in most of its fields of activity. Alzchem benefits from the three very different global developments climate change, population growth and longer life expectancy in a unique way. Alzchem products can offer attractive solutions for achieving the resulting social goals in a multitude of different applications.

The company sees interesting growth prospects for itself in the areas of human and animal nutrition and agriculture in particular. As a result of population growth, it is necessary to achieve efficient food production. Pharmaceutical raw materials and creatine products can contribute to a healthy old age as life expectancy increases. Alzchem is facing up to the goal of sustainability arising from climate change in the field of renewable energies and across the entire company. The fields of fine chemicals and metallurgy offer just as great a perspective.

Alzchem Group AG’s broad product range includes dietary supplements, precursors for corona tests and pharmaceutical raw materials. These products are the company's response to global trends and developments. Alzchem is ideally positioned in this respect and considers itself well prepared for an environmental future and global developments.

The company employs around 1,630 people at four production sites in Germany and a plant in Sweden, as well as three sales companies in the USA, China and UK. Alzchem generated Group sales of around EUR 422.3 million and EBITDA of around EUR 62.0 million in 2021.



End of Media Release


Issuer: Alzchem Group AG
Key word(s): Health

31.08.2022 CET/CEST Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Alzchem Group AG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
Germany
Phone: +498621862888
Fax: +49862186502888
E-mail: ir@alzchem.com
Internet: www.alzchem.com
ISIN: DE000A2YNT30
WKN: A2YNT3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart
EQS News ID: 1432203

 
End of News DGAP Media

1432203  31.08.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1432203&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Alzchem Group AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.